✦ LIBER ✦

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection

✍ Scribed by I. Yamada; F. Suzuki; N. Kamiya; K. Aoki; Y. Sakurai; M. Kano; H. Matsui; H. Kumada

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Virological response and safety of 24-we

✍ J. Toyota; I. Ozeki; Y. Karino; Y. Asahina; N. Izumi; S. Takahashi; Y. Kawakami; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

Rapid loss of hepatitis C virus genotype

✍ Fumitaka Suzuki; Norio Akuta; Yoshiyuki Suzuki; Hitomi Sezaki; Hiromi Yatsuji; Y 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB

757 OUTCOME OF PEGINTERFERON ALFA-2B AND

✍ O. Itaru 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

963 SAFETY AND A ANTIVIRAL ACTIVITY OF A

✍ I. Ozeki 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Characterization of vaniprevir, a hepati

✍ Lawitz, Eric; Sulkowski, Mark; Jacobson, Ira; Kraft, Walter K.; Maliakkal, Bened 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 367 KB

733 Interim (week 12) phase 2b virologic

✍ S. Zeuzem; Y. Benhamou; D. Shouval; V. Bain; S. Pianko; R. Flisiak; M. Grigoresc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 114 KB